Aclaris Therapeutics Inc
Company Profile
Business description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Contact
701 Lee Road
Suite 103
WaynePA19087
USAT: +1 484 324-7933
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
64
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,787.30 | 15.30 | 0.17% |
| CAC 40 | 7,662.59 | 3.32 | -0.04% |
| DAX 40 | 23,673.29 | 236.32 | -0.99% |
| Dow JONES (US) | 44,494.94 | 400.17 | 0.91% |
| FTSE 100 | 8,785.33 | 24.37 | 0.28% |
| HKSE | 24,144.10 | 71.82 | 0.30% |
| NASDAQ | 20,202.89 | 166.84 | -0.82% |
| Nikkei 225 | 39,582.99 | 403.34 | -1.01% |
| NZX 50 Index | 12,789.83 | 55.30 | 0.43% |
| S&P 500 | 6,198.01 | 6.94 | -0.11% |
| S&P/ASX 200 | 8,553.70 | 12.60 | 0.15% |
| SSE Composite Index | 3,453.01 | 4.73 | -0.14% |